TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

HAE TREATMENT GUIDELINES

The US Hereditary Angioedema Association (HAEA) Medical Advisory Board published guidelines to assist you in treating your patients with hereditary angioedema (HAE). These guidelines, published in 2020, reflect scientific and clinical progress, and therapeutic options.1

When developing a comprehensive care plan for you patients with HAE, consider the following evidence-based recommendations.

Lexi, a real TAKHZYRO® (lanadelumab-flyo) patient, walking.

Lexi

Real TAKHZYRO patient
Lexi, a real TAKHZYRO® (lanadelumab-flyo) patient, walking.

Lexi

Real TAKHZYRO patient

Guidelines from the 2020 US HAEA recommend a preventive treatment for appropriate HAE patients1

Preventive treatment, or long-term prophylaxis, refers to the regular use of medication to reduce the severity and frequency of HAE attacks. The decision on when to initiate preventive treatment should reflect the needs of the individual patient.

When evaluating an individual for preventive treatment, consider the patient’s preferences in the context of attack frequency, attack severity, comorbid conditions, and access to emergent treatment. Because disease severity may change over time, the need to start or continue preventive treatment should be periodically reviewed and discussed with the patient.

Clipboard icon.

The US HAEA recommends TAKHZYRO as one of the first-line preventive therapy.1

See takhzyro efficacy

HAE management plan considerations1

Based on recommendations from the HAEA guidelines, keep the following in mind while creating an individualized management plan for your HAE patients.

On-demand treatment1

HAE attacks can still occur despite the use of preventive treatment. As a result, all HAE patients should always keep on-demand, or acute, treatment on hand. TAKHZYRO is not an on-demand treatment.

Encourage patients to periodically check the date of their on-demand treatment to make sure it hasn’t expired. Would you like to continue learning about acute treatment?

See one option

Coordination of care1

HAE-specific information should be communicated with the patient and other healthcare specialists on the patient’s care team. The patient’s local primary healthcare team, emergency department, and hospital should be familiarized with the patient’s HAE treatment plan in case emergency care is needed.

Patients with HAE are encouraged to carry a wallet card or letter from their HAE treatment specialist that summarizes the condition, the patient’s treatment plan, and the HAE treatment specialist’s contact information.

Patient education1

Patients and families should be educated on HAE and how to manage the condition. The genetic nature of the condition and the importance of family testing should be communicated.

For educational resources and information you can pass along to your patients, visit the US HAEA, a patient support and advocacy organization that serves patients with HAE.

Go to HAEA.org

Monitoring1

Patients with HAE should continue to see their HAE-treating physician on a regular basis in order to review and adjust their management plan as needed. Patients should be encouraged to keep track of their HAE symptoms and their medication use. This information can be used to help inform your future medical decisions.

To help your patients taking TAKHZYRO stay on track with treatment, you can encourage them to set up dosing reminders through the TAKHZYRO Text Reminder Program. This will deliver reminders straight to their mobile phone whenever it's time to take TAKHZYRO.

Patients can sign up here

Connect patient with support, including information tailored to their needs.

See patient resources

Reference: 1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046